Back to TAKView full pipeline
Phase 3
Development Phase
2
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
Upcoming Catalysts
What are catalysts?Competitive Landscape
21 competitors in Multiple Myeloma
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA11/21/2016
Ninlaro
Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Orphan
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
REPLAGALPhase 3
Fabry Disease
Alogliptin and pioglitazonePhase 3
Type 2 Diabetes Mellitus
IGSCPhase 3
Primary Immunodeficiency Disease
HYQVIAPhase 3
Primary Immunodeficiency Diseases (PID)
Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medicationsPhase 3
Hypertension
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
